Primary source: Open Government Licence v3.0
The amendments propose clearer legal powers for MHRA to share information regarding medicines and devices, automatic updates to legislation reflecting advances in science, and future enabling powers for a medical device licensing regime.
The proposed changes could significantly impact the regulation of medicines and medical devices, ensuring a more responsive and efficient regulatory environment that aligns with advancements in healthcare technology.
Organizations involved in medical device compliance should prepare for potential future changes requiring MHRA-issued licenses for devices entering the market.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Organizations involved in medical device compliance should prepare for potential future changes requiring MHRA-issued licenses for devices entering the market.
The MHRA has proposed amendments to the Health Bill aimed at modernizing the UK regulatory framework for medicines and medical devices. Key areas of focus include clearer information sharing powers, updates to regulatory legislation, and future medical device licensing capabilities.
What changed: The amendments propose clearer legal powers for MHRA to share information regarding medicines and devices, automatic updates to legislation reflecting advances in science, and future enabling powers for a medical device licensing regime.
Why it matters: The proposed changes could significantly impact the regulation of medicines and medical devices, ensuring a more responsive and efficient regulatory environment that aligns with advancements in healthcare technology.
Practical implication: Organizations involved in medical device compliance should prepare for potential future changes requiring MHRA-issued licenses for devices entering the market.
Published from the regulator source ingestion pipeline after PV impact triage.
Healthcare professionals should not initiate treatment with Avacopan Vifor for new patients and must review existing patients' treatment plans to ensure safe transitions to alternative therapies.
Manufacturers must familiarize themselves with the new procedure, including creating an EMA account and understanding the timelines for submitting the required briefing documents according to the established timetable for 2025 and 2026.
Companies preparing 510(k) submissions for dental composite resin devices must align with the recommendations specified in the new guidance, which include detailed testing and labeling criteria.
Manufacturers should align their premarket submissions for dental curing lights with the updated FDA guidance, ensuring to follow new recommendations on device description, performance testing, and labeling.
